Summary
A world of potential exists where natural language processing (NLP) and generative artificial intelligence (AI) intersect with the fields of precision medicine and life sciences. In this paper, we examine the nuances and complexity of AI tools – including advanced models like ChatGPT – and the importance of biomedical domain expertise when extracting insights from sources such as patient data, drug labels, and medical literature.
Learn how NLP and generative AI contribute to:
-
Optimizing clinical trials: AI technology helps to streamline the design and patient recruitment processes, increasing the likelihood of successful trial outcomes.
-
Enhancing adverse drug reaction (ADR) analysis: Refining ADR data analysis contributes to improved drug safety and pharmacovigilance.
-
Improving drug discovery and repurposing: AI accelerates hypothesis generation and literature analysis to support new drug development and existing drug reapplication.
Featured speaker(s)
April Curtis
Marketing Director
IMO
Thomas Magnum
Marketing Manager
IMO
B.A. Baracus
Data Analyst
IMO
B.A. Baracus
Data Analyst
IMO
